Early-stage study marks milestone for regenerative medicine
News
Jascayd gains UK licence for treatment of pulmonary fibrosis
New option for adults with IPF and PPF
Grünenthal receives FDA designations for tegacorat in Duchenne muscular dystrophy
SEGRAM aims to offer an alternative to glucocorticoid‑based treatment
Compass Pathways reports six‑month data confirming durable profile of COMP360
Second phase 3 trial shows sustained benefit and supports forthcoming regulatory submission
Ferrer and Prilenia begin confirmatory study of pridopidine in Huntington’s disease
New phase 3 trial to assess impact on disease progression, function and quality of life
Wegovy pill launches in UK as first daily oral GLP‑1 for weight management
Option offers once‑daily semaglutide tablets for adults living with obesity
Sofinnova reports Myricx Bio to be acquired by Novartis
Deal brings together Novartis oncology capabilities with Myricx Bio’s next‑gen ADC platform
Francis Crick Institute and Medicines Discovery Catapult open applications for next KQ Labs cohort
Accelerator seeks early‑stage data‑driven health ventures for five‑month programme
Novartis receives European Commission approval for Itvisma for spinal muscular atrophy
EC backs first gene replacement therapy for broad sma population
AlzeCure enters collaboration agreement with QuantumCell ApS for NeuroRestore project
QuantumCell gains global rights to NeuroRestore platform in deal worth over USD 2.2 billion
R1 Therapeutics forms advisory board to support advancement of AP306
Experts join new group as therapy moves into phase 2b
UAE launches first genomics-driven clinical trial to prevent Alzheimer’s disease
IROS and partners use Emirati Genome Programme to identify high-risk individuals before symptoms appear
Viridian wins FDA approval for Lumvoa for thyroid eye disease
Company secures first commercial product with data for active and chronic TED
Racura treats first patient in phase 1 HARNESS‑1 lung cancer trial
No adverse events observed as study begins in EGFR‑mutant NSCLC
NICE recommends MSD’s pembrolizumab for locally advanced cervical cancer
First immunotherapy approved for LACC in England offers new treatment option for women
